August 7, 2024 07:08 AM EDTUpdated 09:06 AM
R&D
Pharma

Up­dat­ed: No­vo Nordisk yanks We­govy fil­ing for heart fail­ure from FDA, will re­sub­mit next year

Reynald Castañeda

Deputy Editor

No­vo Nordisk is run­ning in­to a speed bump with We­govy’s la­bel ex­pan­sion ef­forts in heart dis­ease as it has pulled its FDA sub­mis­sion in heart …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times